What HAS-BLED score is high risk?

A HAS-BLED score of ≥ 3 is considered high risk, associated with approximately 3.74 or more major bleeding events per 100 patient-years. However, a high HAS-BLED score should prompt identification and correction of modifiable bleeding risk factors, not automatic anticoagulation cessation.

Can I stop warfarin if the HAS-BLED score is high?

No. The ESC 2020 AF guidelines explicitly state that a high HAS-BLED score (≥ 3) should NOT automatically lead to withholding anticoagulation. Instead, use it to identify and correct modifiable factors: control blood pressure, address labile INR, review antiplatelets/NSAIDs, and counsel on alcohol reduction. For most AF patients with CHA₂DS₂-VASc ≥ 2, the stroke prevention benefit of anticoagulation exceeds the bleeding risk.

Does HAS-BLED apply to patients on DOACs?

HAS-BLED was originally validated in warfarin-treated patients. It can be applied to DOAC-treated patients, but the "Labile INR" criterion (L) does not apply, slightly reducing the maximum score. The other HAS-BLED criteria remain clinically relevant for DOAC-treated patients.

What are the modifiable HAS-BLED risk factors?

Modifiable HAS-BLED factors include: (1) H — Uncontrolled hypertension: treat to SBP < 140 mmHg. (2) A — Labile INR: switch to DOAC or optimize warfarin management. (3) D — Antiplatelet/NSAID use: review necessity; avoid if possible. (4) D — Alcohol excess: counseling and reduction. Non-modifiable factors include stroke history, age, and prior bleeding history.

Medically Reviewed · CliniqWise Clinical Advisory Board — Cardiology & Anticoagulation Panel · Updated 2026-08-27

HAS-BLED Score Calculator — Bleeding Risk Assessment in Atrial Fibrillation

Calculate the HAS-BLED score to estimate major bleeding risk in patients with atrial fibrillation on anticoagulation therapy, identifying modifiable risk factors.

🩺

HAS-BLED Score Calculator

Enter values below to calculate

H — Uncontrolled Hypertension (SBP > 160 mmHg)*

A — Abnormal Renal Function (dialysis, transplant, or Cr > 200 µmol/L)*

A — Abnormal Liver Function (cirrhosis or bilirubin/transaminase elevation)*

S — Stroke / TIA History*

B — Bleeding History or Predisposition*

L — Labile INR (TTR < 60% on warfarin)*

E — Elderly (Age > 65 years)*

D — Antiplatelets or NSAIDs*

D — Alcohol Excess (≥ 8 drinks/week)*

This calculator is for informational and educational purposes. Results should be interpreted with clinical judgment and local guidelines.

What is the HAS-BLED Score?

The HAS-BLED score is a validated clinical tool developed to estimate the annual risk of major bleeding in patients with atrial fibrillation (AF) receiving anticoagulation therapy. Published by Pisters et al. in 2010 from the Euro Heart Survey on AF, HAS-BLED assesses seven clinical parameters: Hypertension (uncontrolled), Abnormal renal/liver function, Stroke history, Bleeding history or predisposition, Labile INR (time in therapeutic range < 60%), Elderly (age > 65), and Drugs/alcohol use. Each criterion scores 1 or 2 points for a maximum of 9 points. Crucially, the ESC 2020 AF guidelines emphasize that HAS-BLED should be used to identify and correct MODIFIABLE bleeding risk factors (uncontrolled BP, labile INR, concurrent antiplatelet/NSAID use, alcohol excess) rather than as a reason to withhold anticoagulation, since the stroke risk from untreated AF typically exceeds the bleeding risk in most patients.

HAS-BLED Score = H (Hypertension) + A (Abnormal renal/liver function, 1 or 2) + S (Stroke history) + B (Bleeding history/predisposition) + L (Labile INR) + E (Elderly age > 65) + D (Drugs/alcohol, 1 or 2). Score 0–1: Low risk; Score 2: Moderate risk; Score ≥ 3: High risk (~3.74 bleeds/100 patient-years).

When to Use the HAS-BLED Score

Annual or reassessment of major bleeding risk in all AF patients being considered for or already receiving anticoagulation therapy with warfarin or DOACs (apixaban, rivaroxaban, dabigatran, edoxaban).
Identification of correctable bleeding risk factors before initiating anticoagulation: uncontrolled hypertension correction, labile INR management, antiplatelet/NSAID review, and alcohol use assessment.
Routine annual review of anticoagulated AF patients at cardiology or anticoagulation clinic follow-up, documenting changes in HAS-BLED score and addressing modifiable factors.
Shared decision-making consultations: Providing patients with a balanced, quantified understanding of bleeding risk alongside CHA₂DS₂-VASc stroke risk to facilitate informed anticoagulation decisions.
Acute clinical decisions: Assessing bleeding risk before procedures (cardioversion, catheter ablation, cardiovascular interventions) requiring temporary anticoagulation bridging or interruption.

Atrial FibrillationWarfarin TherapyDOAC TherapyAnticoagulation ManagementStroke PreventionIntracranial Haemorrhage HistoryGastrointestinal BleedingChronic Kidney Disease on Anticoagulants

HAS-BLED Score Criteria — Clinical Parameters

HAS-BLED Total Score

HAS-BLED = H + A (0–2) + S + B + L + E + D (0–2). Maximum = 9 points.

Patient with uncontrolled HTN (1) + abnormal renal function (1) + stroke history (1) + age 72 (1) = Score 4 → High bleeding risk; address modifiable factors.

Variables

H — Hypertension (+1 point)

Uncontrolled hypertension: systolic BP > 160 mmHg. Controlled hypertension does NOT score a point.

A — Abnormal Renal/Liver Function (+1 or +2 points)

Renal: dialysis, transplant, or creatinine > 200 µmol/L (+1). Liver: chronic hepatic disease or bilirubin >2×ULN + ALT/AST/ALP >3×ULN (+1). Each scores 1 point independently (max +2).

S — Stroke History (+1 point)

Previous stroke, TIA, or thromboembolism history.

B — Bleeding History or Predisposition (+1 point)

Prior major bleeding, anemia, or significant bleeding predisposition (thrombocytopenia, bleeding disorder).

L — Labile INR (warfarin only) (+1 point)

Unstable/high INR, or time in therapeutic range (TTR) < 60% when on warfarin. Not applicable for DOACs.

E — Elderly (Age > 65) (+1 point)

Age > 65 years at time of assessment. Some sources define "elderly" as ≥ 75 years — check guideline version.

D — Drugs/Alcohol (+1 or +2 points)

Antiplatelet agents or NSAIDs (+1). Alcohol excess (≥ 8 drinks/week) (+1). Each scores 1 point independently (max +2).

A high HAS-BLED score (≥ 3) should NOT automatically lead to withholding anticoagulation. Instead, it signals the need to identify and correct modifiable risk factors. The net clinical benefit of anticoagulation in AF almost always exceeds bleeding risk in patients with CHA₂DS₂-VASc ≥ 2.

HAS-BLED Score Interpretation & Clinical Action

ESC 2020 Guidelines recommend using HAS-BLED to identify correctable bleeding risk factors, not to determine whether to anticoagulate AF patients. The score estimates annual risk of major bleeding events (requiring hospitalization, causing >2g/dL Hb drop, or requiring transfusion).

Range	Classification	Health Risk
0 (Low risk)	Low Bleeding Risk	~0.9 major bleeds/100 patient-years. Anticoagulate per stroke risk (CHA₂DS₂-VASc).
1 (Low risk)	Low Bleeding Risk	~1.02 bleeds/100 patient-years. Anticoagulate; annual reassessment.
2 (Moderate risk)	Moderate Bleeding Risk	~1.88 bleeds/100 patient-years. Address modifiable factors; close monitoring.
3 (High risk)	High Bleeding Risk	~3.74 bleeds/100 patient-years. Anticoagulate but actively correct ALL modifiable factors.
4 (High risk)	High Bleeding Risk	~8.70 bleeds/100 patient-years. Specialist review; consider risk-benefit discussion. Do not withhold anticoagulation without specialist input.
≥ 5 (Very high risk)	Very High Bleeding Risk	Highest risk tier. Multidisciplinary specialist review mandatory. Anticoagulation must be carefully considered vs. alternative stroke prevention strategies.

HAS-BLED must ALWAYS be used alongside CHA₂DS₂-VASc. A high HAS-BLED score with a high CHA₂DS₂-VASc score almost universally favors anticoagulation (net benefit). Untreated AF stroke is typically more devastating than anticoagulation-associated bleeding.

HAS-BLED Score Limitations & Clinical Warnings

HAS-BLED does NOT preclude anticoagulation: ESC 2020 and NICE guidelines explicitly state that HAS-BLED ≥ 3 should prompt modifiable risk factor review, NOT automatic anticoagulation cessation.

Validated primarily in warfarin-treated AF patients: Most original HAS-BLED validation studies used warfarin. The "Labile INR" criterion is not applicable for DOAC-treated patients, slightly reducing maximum possible score.

Does not distinguish type of bleeding: HAS-BLED predicts all major bleeding events equally, including both intracranial hemorrhage (most feared) and gastrointestinal bleeding (most common). ICH risk is separately important to assess.

Annual rate estimates are population-level: Individual patient bleeding risk may differ significantly based on unmeasured factors. Use as a guide, not a precise individual prediction.

Does not account for all DOAC-specific bleeding risks: Factors such as renal function (particularly for dabigatran) and low body weight (apixaban/edoxaban) affect DOAC bleeding risk but are not fully captured.

Competing risk tools: ATRIA and ORBIT bleeding risk scores have been validated and may perform comparably. No single tool is definitively superior; clinical context determines tool choice.

Medical Disclaimer

HAS-BLED calculation must be performed and interpreted by a qualified cardiologist, physician, or anticoagulation specialist. Anticoagulation management in AF requires holistic assessment of stroke risk, bleeding risk, patient preferences, and comorbidities. Never stop anticoagulation based on HAS-BLED score alone without specialist review.

References & Citations

Pisters R, Lane DA, Nieuwlaat R, et al.. “A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation”. Chest. 2010. 138(5): 1093–1100. PMID: 20299623 | DOI: 10.1378/chest.10-0134
Hindricks G, Potpara T, Dagres N, et al.. “2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation”. European Heart Journal. 2021. 42(5): 373–498. PMID: 32860505 | DOI: 10.1093/eurheartj/ehaa612
Lip GYH, Andreotti F, Fauchier L, et al.. “Bleeding risk assessment and management in atrial fibrillation patients: an European Heart Rhythm Association position document”. Europace. 2011. 13(5): 723–746. PMID: 21515269 | DOI: 10.1093/europace/eur126

Medically Reviewed

Reviewed by CliniqWise Clinical Advisory Board — Cardiology & Anticoagulation Panel · Last updated: 2026-08-27 · Next review: 2027-02-27

Frequently Asked Questions

Common Questions About HAS-BLED Score Calculator

Explore More Medical Calculators

Browse the CliniqWise calculator library by specialty, score, disease area, or clinical task.

Browse All Calculators